ATRA
NASDAQ
US
Atara Biotherapeutics, Inc. - Common Stock
$4,99
▼ $-0,18
(-3,48%)
Vol. 47K
7
Punteggio di Qualità
fail
Ricavi ✗
Utile netto ✗
>IPO ✗
Cap. mercato
$130.4M
P/E
5,6
ROE
-315,4%
Margine
15,4%
D/E
12,00
Beta
-0,40
52W
$5–$19
Consenso Wall Street
10 analisti · Apr 20262
Acquisto forte
5
Compra
2
Mantieni
1
Vendi
0
Vendita forte
70,0%
Rating Compra
Grafico dei Prezzi
Titoli simili
Utili
Tasso di battuta: 80,0%
Prossimo report
Mag 13, 2026
Stima EPS: $-0,41
| Trimestre | EPS Stimato | EPS Effettivo | Sorpresa |
|---|---|---|---|
| Mar 2026 | $-0,41 | — | — |
| Dic 2025 | $-0,17 | $-0,25 | $-0,08 |
| Set 2025 | $-0,88 | $-0,32 | +$0,56 |
| Giu 2025 | $-0,47 | $0,19 | +$0,66 |
Ricavi e utili trimestrali
| Trimestre | 2024-0… | 2024-1… | 2025-0… | 2025-0… | 2025-0… | 2025-1… |
|---|---|---|---|---|---|---|
| Ricavi | — | $32.8M | $98.1M | $17.6M | $3.5M | $1.6M |
| Utile netto | — | -$12.7M | $38.0M | $2.4M | -$4.3M | -$3.4M |
Trend fondamentali
| Metrica | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | — | -315.4% | -315.4% | -315.4% | -315.4% | -315.4% |
| P/E (TTM) | 8.92 | 13.91 | 17.37 | 18.00 | 3.77 | 5.57 |
| Net Margin | 13.6% | 3.1% | 3.1% | 3.1% | 15.4% | 15.4% |
| Gross Margin | 96.8% | 81.2% | 81.2% | 81.2% | 81.6% | 81.6% |
| D/E Ratio | — | 12.00 | 12.00 | 12.00 | 12.00 | 12.00 |
| Current Ratio | 1.70 | 1.70 | 1.70 | 1.70 | 1.02 | 1.02 |
Rapporti chiave
ROA (TTM)
39,3%
P/S (TTM)
0,86
P/B
2,5
EPS (TTM)
$2,19
CF/Share
$-2,73
Crescita ricavi 3A
+85,1%
52W High
$18,95
52W Low
$5,01
$5,01
Intervallo 52 settimane
$18,95
Salute finanziaria
Flusso di cassa libero
-$5.7M
Debito netto
$1.9M
Liquidità
$8.5M
Debito totale
$10.4M
Aggiornato al Dic 31, 2025
Як ATRA виглядає на тлі конкурентів у Biotechnology?
Група порівняння: Micro-cap Biotechnology (All) · 528 компаній
Оцінка ATRA vs аналоги Biotechnology
P/E
5,6
▼
70%
sotto
peer
(18,8)
vs Peer
vs Settore
Sottovalutato
P/S
0,9
▼
93%
sotto
peer
(12,9)
vs Peer
vs Settore
Sottovalutato
P/B
2,5
▼
0%
sotto
peer
(2,5)
vs Peer
vs Settore
Valore equo
Дивідендна дохідність
—
▼
0%
sotto
peer
(0,0%)
vs Peer
vs Settore
Rendimento basso
Прибутковість ATRA vs аналоги Biotechnology
ROE
-315,4%
▼
369%
sotto
peer
(-67,3%)
vs Peer
vs Settore
Debole
Net margin
15,4%
▲
105%
sopra
peer
(-286,8%)
vs Peer
vs Settore
Sotto media
Валова маржа
81,6%
▲
4%
sopra
peer
(78,6%)
vs Peer
vs Settore
Debole
ROA
39,3%
▲
184%
sopra
peer
(-46,7%)
vs Peer
vs Settore
Top livello
Фінансове здоровʼя ATRA vs аналоги Biotechnology
D/E ratio
12,0
▼
0%
sotto
peer
(0,0)
vs Peer
vs Settore
Debito alto
Поточна ліквідність
1,0
▼
77%
sotto
peer
(4,4)
vs Peer
vs Settore
Liquidità bassa
Beta
-0,4
▼
141%
sotto
peer
(1,0)
vs Peer
vs Settore
Più volatile
Радар фундаменталів ATRA
ATRA
Mediana peer
Industria
ATRA прибутковість vs борг
Розмір бульбашки = капіталізація · X = чиста маржа · Y = D/E ratio
ATRA vs аналоги: ключові метрики
Attività insider
NeutralAcquisti
0
Vendite
0
PANACEA INNOVATION LTD
Beneficial Owner of more than… · Mar 17
259163 shs
GRANT-HUERTA YANINA
Officer · Mar 09
20300 shs
NGUYEN ANHCO T
Chief Executive Officer · Mar 02
2996 shs
GRANT-HUERTA YANINA
Officer · Mar 02
2104 shs
PANACEA INNOVATION LTD
Beneficial Owner of more than… · Gen 12
80554 shs
Ultimo 90 giorni
Principali azionisti
Top 5: 17,93%EcoR1 Capital, LLC
7,01%
$2.6M
Redmile Group, LLC
5,40%
$2.0M
Vanguard Group Inc
2,76%
$1.0M
Marshall Wace LLP
1,82%
$682K
Globeflex Capital L P
0,94%
$354K
Aggiornato al Dic 31, 2025